FDA advisors to review COVID-19 shots for young kids, new boosters in

(Reuters) – The U.S. Food and Drug Administration said an advisory panel of experts would hold meetings this month to discuss authorizing booster doses of Moderna (NASDAQ:) Inc and Johnson & Johnson (NYSE:)’s COVID-19 vaccines, and clearing Pfizer ‘s vaccine for use in children.

The panel will discuss authorizing Pfizer Inc (NYSE:)’s COVID-19 vaccine for children aged five through 11 on Oct. 26, the FDA said on Friday.

Last month, the FDA authorized https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-authorize-third-dose-pfizer-covid-19-vaccine-older-americans-bloomberg-2021-09-22 a booster dose of the Pfizer and BioNTech vaccine for older adults and some Americans at high-risk of illness.

Roughly 4 million Americans have received a booster dose as of Thursday, according to data from the Centers for Disease Control and Prevention.

The panel, called the Vaccines and Related Biological Products Advisory Committee, will hold a meeting on Oct. 14 to discuss a booster dose of the Moderna vaccine, and discuss J&J’s boosters on Oct. 15.

The panel will also review data on receiving a booster dose of a different vaccine than the one used in the original vaccine series.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.